STOCK TITAN

Axsome Therapeutics, Inc (AXSM) Free Cash Flow by Year

AXSM

Axsome Therapeutics, Inc recorded an outflow of $93.9M in free cash flow in fiscal year 2025. This represents an increase of 27.0% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to an outflow of $72.0M in free cash flow. The table below carries 12 fiscal years, from 2014 to 2025, and the quarters Axsome Therapeutics, Inc has filed alongside them.

FY2025 annual
Free Cash Flow -$93.9M
YoY +27.0%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

AXSM Free Cash Flow by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY21DEF 14AFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-K
Free Cash Flow-$72.0M-$93.9M+27.0%-$128.7M+11.7%-$145.7M-24.3%-$117.2M-8.0%-$108.5M-38.3%-$78.5M-69.2%-$46.4M-54.2%-$30.1M-13.6%-$26.5M-23.8%-$21.4M-186.7%-$7.5MN/A

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

AXSM Free Cash Flow by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Free Cash Flow-$33.4M-3.0%-$20.8M+52.4%-$18.7M+28.6%$988K+105.3%-$32.4M-7.5%-$43.7M+18.4%-$26.2M+13.6%-$18.7M+65.3%-$30.2M+45.6%-$53.6M-809.1%-$30.4M-9.5%-$53.9M-136.2%

What free cash flow means

Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.

More Axsome Therapeutics, Inc financials

Frequently Asked Questions

What was Axsome Therapeutics, Inc's free cash flow in fiscal year 2025?

Axsome Therapeutics, Inc recorded an outflow of $93.9M in free cash flow in fiscal year 2025.

How fast is Axsome Therapeutics, Inc's free cash flow growing?

Axsome Therapeutics, Inc (AXSM) free cash flow rose by 27.0% year over year, from -$128.7M to -$93.9M in fiscal year 2025.

What is Axsome Therapeutics, Inc's free cash flow over the last twelve months?

Axsome Therapeutics, Inc (AXSM) reported an outflow of $72.0M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Axsome Therapeutics, Inc (AXSM) reported -$33.4M in free cash flow in Q2 2026. This represents a decrease of 3.0% from the same quarter a year earlier.

Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Axsome Therapeutics, Inc (AXSM) reported on that line in every period on record.